The State of Cell and Gene Therapy 2025
REGISTER NOW
Broadcast Date: Wednesday, January 29, 2025Time: 8:00 am PT, 11:00 am ET, 17:00 CET The field of cell and gene therapy has seen a wave of exciting advances in the past 12...
bit.bio raises $30 million led by M&G Investments
bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company. Existing investors, including ARCH...
Nvidia’s Venture Arm Raises Stake in AI Drug Discoverer Genesis Therapeutics
Evan Feinberg, PhD, founder and CEO of Genesis Therapeutics
In the beginning, Genesis Therapeutics spun out from the Stanford University lab of Vijay Pande, PhD, where Evan Feinberg, PhD, then a graduate student, co-invented and...
Breakthrough microchip technology enables multi-disease detection
In a world grappling with a multitude of health threats -; ranging from fast-spreading viruses to chronic diseases and drug-resistant bacteria -; the need for quick, reliable, and easy-to-use home diagnostic tests has never...
S. aureus Vaccine Failures Linked to Interleukin Production, Antibody Inactivation
Staphylococcus aureus (S. aureus; SA/Sa) is a major cause of skin and soft tissue infections that can sometimes lead to sepsis and toxic shock syndrome. And while many S. aureus vaccine candidates have been effective...
Novel drug holds promise for treating Duchenne muscular dystrophy
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an experimental compound called K884 can boost the...
A new era of targeted therapy with antibody–drug conjugates
insights from industryGrace LiuTechnical Account ManagerSino Biological In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs....
Signal Peptide Harnesses Exosomes for Precise Drug Delivery
Drug discovery and novel disease treatments are major areas of research, with constant innovation. Delivering these drugs and treatments completely and precisely has been a major hurdle that researchers continue to grapple with.
Now,...
New protein platform enhances cancer immunotherapy
Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs...
Insilico Medicine gets first clinical milestone payment of $10 million for XL309
Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091)...
